On Monday, C4 Therapeutics Inc (NASDAQ: CCCC) was -5.49% drop from the session before settling in for the closing price of $4.55. A 52-week range for CCCC has been $1.06 – $11.88.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 7.65%. When this article was written, the company’s average yearly earnings per share was at 43.52%. With a float of $56.67 million, this company’s outstanding shares have now reached $70.56 million.
The extent of productivity of a business whose workforce counts for 145 workers is very important to gauge. In terms of profitability, gross margin is 76.78%, operating margin of -354.44%, and the pretax margin is -312.52%.
C4 Therapeutics Inc (CCCC) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward C4 Therapeutics Inc stocks. The insider ownership of C4 Therapeutics Inc is 19.72%, while institutional ownership is 83.25%. The most recent insider transaction that took place on Nov 18 ’24, was worth 54,532. Before that another transaction happened on Oct 18 ’24, when Company’s Director proposed sale 13,000 for $6.41, making the entire transaction worth $83,321.
C4 Therapeutics Inc (CCCC) Performance Highlights and Predictions
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -0.68 earnings per share (EPS) during the time that was better than consensus figure (set at -0.69) by 0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.52 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 43.52% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 22.30% during the next five years compared to -36.05% drop over the previous five years of trading.
C4 Therapeutics Inc (NASDAQ: CCCC) Trading Performance Indicators
You can see what C4 Therapeutics Inc (CCCC) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 6.31. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.01.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.70, a number that is poised to hit -0.49 in the next quarter and is forecasted to reach -1.57 in one year’s time.
Technical Analysis of C4 Therapeutics Inc (CCCC)
The latest stats from [C4 Therapeutics Inc, CCCC] show that its last 5-days average volume of 1.14 million was inferior to 2.09 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 69.86%. Additionally, its Average True Range was 0.40.
During the past 100 days, C4 Therapeutics Inc’s (CCCC) raw stochastic average was set at 12.04%, which indicates a significant decrease from 22.44% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 78.41% in the past 14 days, which was lower than the 85.48% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.48, while its 200-day Moving Average is $6.35. Now, the first resistance to watch is $4.48. This is followed by the second major resistance level at $4.66. The third major resistance level sits at $4.76. If the price goes on to break the first support level at $4.20, it is likely to go to the next support level at $4.10. Assuming the price breaks the second support level, the third support level stands at $3.92.
C4 Therapeutics Inc (NASDAQ: CCCC) Key Stats
There are 70,589K outstanding shares of the company, which has a market capitalization of 303.53 million. As of now, sales total 20,760 K while income totals -132,490 K. Its latest quarter income was 15,360 K while its last quarter net income were -24,670 K.
